Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen
In a report published Friday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ: PCYC), and raised the price target from $233.00 to $261.00.
In the report, Credit Suisse noted, "We are increasing our target price to $261, the agreed purchase price from ABBV, from $233. We believe the probability of the deal closing is very high. PCYC's remarkable rise highlights the power of a truly novel, first-in-class drug to both impact patients and create huge value for shareholders. We view the ABBV deal as rational, creating the leading franchise in CLL and NHL, with potential upside in solid tumors, multiple myeloma, and autoimmune disease. Given all that has been said about the drug, the deal price, and the strategic rationale, we thought it was worthwhile reflecting on some of the champions of this program at PCYC (see page 2 for our thoughts on the deal)."
Pharmacyclics closed on Thursday at $254.22.
Latest Ratings for PCYC
Mar 2015 | Leerink Swann | Downgrades | Outperform | Market Perform |
Mar 2015 | Nomura | Downgrades | Buy | Neutral |
Mar 2015 | Wells Fargo | Downgrades | Outperform | Market Perform |
View More Analyst Ratings for PCYC
View the Latest Analyst Ratings
See more from Benzinga
Credit Suisse Continues To See Schlumberger As Top Large-Cap OFS Pick
Credit Suisse Reiterates Neutral, Raises PT On Walgreens Boots Alliance On Balanced Risk/Reward
UPDATE: Credit Suisse Downgrades Esterline Technologies Following Disappointing FQ1 Report
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.